Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

SANOFI : Gets a Neutral rating from Berenberg

share with twitter share with LinkedIn share with facebook
09/29/2020 | 06:05am EDT

Berenberg changes its rating and switches from Buy to Neutral. The target price is unchanged at EUR 92.

© MarketScreener with dpa-AFX Analyser 2020

share with twitter share with LinkedIn share with facebook
All news about SANOFI
10/30SANOFI : - Safety and efficacy of Dupixent in patients as young as 6 years with ..
AQ
10/30SANOFI : Q3 2020 business EPS(1) growth of 8.8% at CER
AQ
10/30SANOFI : to evaluate the safety and efficacy of novel investigational candidate ..
AQ
10/30REGENERON PHARMACEUTICALS INC. : - Dupixent Efficacy and Safety in Patients as Y..
AQ
10/30REGENERON PHARMACEUTICALS : FDA Accepts for Priority Review Libtayo for Advanced..
AQ
10/30SANOFI : Receives a Buy rating from Credit Suisse
MD
10/30SANOFI : JP Morgan remains its Buy rating
MD
10/30SANOFI : Goldman Sachs keeps its Buy rating
MD
10/29EU to fund transfer of COVID-19 patients across borders to prevent hospitals ..
RE
10/29EU Commission says talking to four companies on COVID vaccine
RE
More news
Financials
Sales 2020 36 320 M 42 295 M 42 295 M
Net income 2020 11 571 M 13 475 M 13 475 M
Net Debt 2020 6 036 M 7 028 M 7 028 M
P/E ratio 2020 8,57x
Yield 2020 4,12%
Capitalization 97 206 M 113 B 113 B
EV / Sales 2020 2,84x
EV / Sales 2021 2,69x
Nbr of Employees 100 409
Free-Float 89,0%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 104,86 €
Last Close Price 77,37 €
Spread / Highest target 58,7%
Spread / Average Target 35,5%
Spread / Lowest Target 9,86%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-13.67%113 280
JOHNSON & JOHNSON-6.01%361 159
ROCHE HOLDING AG-6.13%275 049
PFIZER INC.-9.44%196 047
MERCK & CO., INC.-17.31%191 944
NOVARTIS AG-22.21%177 493